VIDA Diagnostics is a leader in quantitative pulmonary image analysis for the diagnosis and treatment of pulmonary diseases.
VIDA Diagnostics develops and commercializes pulmonary applications, establishing quantitative pulmonary imaging in routine clinical practice. VIDA is an established leader in quantitative lung analysis for COPD, emphysema and asthma, establishing objective, quantitative measures for diagnosis, interventional therapies and therapeutic response assessment.
Participating in the emerging pulmonary device market that is expected to grow to nearly $3.8 billion by 2011, VIDA's vision is to establish lung quantitative CT methods as the standard of care for diagnosis and staging of chronic lung disease. VIDA was founded by four University of Iowa faculty members, Eric Hoffman, Ph.D., Geoffrey McLennan, M.D., Ph.D., Joseph Reinhardt, Ph.D. and, Milan Sonka, Ph.D.
Specialties
Quantitative Pulmonary Imaging, Clinical Validation, COPD and Lung Cancer analysis, Medical Device Software
VIDA Diagnostics Activity on LinkedIn
-
VIDA Diagnostics VIDA Diagnostics Opens First Branch Office in Silicon Valley
